Related Experiment Videos
Iloprost in cardiopulmonary bypass procedures
H R Watson1, G Belcher, J K Brierley
1Cardiovascular Clinical Research Unit, Schering Health Care, West Sussex, England.
Agents and Actions. Supplements
|January 1, 1992
Summary
Iloprost preserves platelet function during cardiopulmonary bypass but does not prevent post-operative cerebral deficits. Its use in severe thrombocytopenia is justified, but routine clinical benefits require further study.
Area of Science:
- Cardiovascular Science
- Hematology
Background:
- Cardiopulmonary bypass (CPB) can impair platelet function.
- Platelet dysfunction increases risks during and after cardiac surgery.
Purpose of the Study:
- To evaluate the effect of iloprost on platelet aggregation during CPB.
- To assess the impact of iloprost on platelet function and cerebral deficits post-CPB.
Main Methods:
- A placebo-controlled study involving 145 patients undergoing CPB.
- Monitoring of platelet numbers, function, and hemodynamic parameters.
- Assessment of post-operative cerebral deficits.
Main Results:
- Iloprost significantly preserved platelet numbers and function.
- No significant adverse hemodynamic effects were observed.
- No reduction in post-operative cerebral deficits was detected.
Conclusions:
- Iloprost demonstrates potential benefits for platelet preservation in CPB patients, especially those with thrombocytopenia.
- Clinical efficacy of iloprost in routine CPB requires additional investigation.